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Abstract (234/250 words). 
 
Considerable uncertainty exists about the defining brain changes associated with bipolar disorder 
(BD). Understanding and quantifying the sources of uncertainty can help generate novel clinical 
hypotheses about etiology and assist in the development of biomarkers for indexing disease 
progression and prognosis. Here we were interested in quantifying case-control differences in 
intracranial volume (ICV) and each of eight subcortical brain measures: nucleus accumbens, 
amygdala, caudate, hippocampus, globus pallidus, putamen, thalamus, lateral ventricles. In a 
large study of 1,710 BD patients and 2,594 healthy controls, we found consistent volumetric 
reductions in BD patients for mean hippocampus (Cohen’s d = -0.232; P=3.50x10-7) and 
thalamus (d = -0.148; P=4.27x10-3) and enlarged lateral ventricles (d = -0.260; P=3.93x10-5) in 
patients. No significant effect of age at illness onset was detected. Stratifying patients based on 
clinical subtype (BD type-I or type-II) revealed that BDI patients had significantly larger lateral 
ventricles and smaller hippocampus and amygdala than controls. However, when comparing BDI 
and BDII patients directly, we did not detect any significant differences in brain volume. This 
likely represents similar etiology between bipolar disorder subtype classifications. Exploratory 
analyses revealed significantly larger thalamic volumes in patients taking lithium compared to 
patients not taking lithium. We detected no significant differences between BDII patients and 
controls in the largest such comparison to date. Findings in this study should be interpreted with 
caution and with careful consideration of the limitations inherent to meta-analyzed neuroimaging 
comparisons. 
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1. Introduction 
Bipolar disorder (BD) is a recurrent, severe illness characterized by episodes of mania (or 
hypomania) and depression, and affects approximately 1 to 3% of the population1. The disease is 
highly heritable2, but the underlying pathophysiology is not yet understood. While structural 
brain abnormalities in BD have been reported, the pattern of structural brain abnormalities based 
on magnetic resonance imaging (MRI) is still not clearly defined. A set of retrospective meta-
analyses of structural MRI studies of BD and healthy controls found right lateral ventricular 
enlargement in patients as the only consistent volumetric difference based on previously 
published studies3-5. However, several studies report detectable differences in the dorsolateral 
prefrontal cortex6, the ventrolateral prefrontal cortex7, and the anterior (ACC) and subgenual 
(sgACC) cingulate cortices8. Meta-analytic studies highlight the substantial heterogeneity across 
studies for several structures of interest, notably the amygdala and thalamus3. Previously, a 
mega-analysis combined data from multiple sites around the world into a single model, and 
found differences in lateral ventricle, temporal lobe, and putamen volume9. 
The sources of the heterogeneity in previously reported findings are likely to be 
multifactorial and complex. Firstly, there may be true biological variability across cohorts, that 
may derive from clinical phenotypes such as disease severity and duration, medication status and 
history, and co-morbidity. One much debated source of bias in the study of brain volumetric 
associations with BD is the effect of mood-stabilizing medications, primarily lithium, which may 
influence brain structure in individual studies10, meta-analyses11, as well as mega-analyses9. 
However, it is difficult to distinguish unique effects of pharmacological agents on brain volumes 
from concurrent effects of clinical and demographic variables which are likely to interact with 
medication status, and may even influence which medications are prescribed. Secondly, 
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variability in the neuroimaging data acquisition, processing, and analysis protocols can affect the 
sensitivity and apparent variability of the brain measures, making it challenging to compare 
different studies directly.  
To address several of these issues, we formed an international collaboration for the study 
of BD as part of the Enhancing Neuroimaging Genetics through Meta-Analysis (ENIGMA) 
Consortium12. Here, we aimed to identify subcortical brain volumetric changes13, 14 that may 
consistently distinguish BD patients from healthy controls using a coordinated meta-analysis 
approach that builds on the work from Hallahan et al., 20119. A number of the studies included 
in this ENIGMA project have examined volumetric brain differences previously (see 
Supplementary Table 2 citations), but this effort combines many new sites and additional data 
in a coordinated analysis. We also aimed to examine and characterize sources of heterogeneity in 
brain imaging volumetric indices using exploratory analyses based on BD subtype (I or II), age 
at illness onset, commonly prescribed medications, and mood state. In the present study, we 
focused on subcortical structures for three primary reasons: 1) they are critically involved in 
emotional response and memory, hallmark behavioral features of BD15-17; 2) they are reliably 
measured across sites, as detailed in extensive comparisons of multi-site/scanner analyses (see 
Supplementary Tables 5 and 6a-h)18, 19; and 3) are key components in dysregulation network 
connections which interplays with the cortex20. 
 
2. Materials and Methods 
2.1 Studies 
Samples contributing to this project and demographics by site are given in Supplementary 
Table 1. Participating sites were contacted to collaborate on this project through the ENIGMA 
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Consortium, after advertising the goals of the project on the ENIGMA website and at numerous 
international conferences in neuroimaging and psychiatry; none of the sites contacted refused or 
were unable to participate in this project. In total, data from 4,304 subjects including 1,710 cases 
and 2,594 healthy controls were available for analysis. Each participating site obtained approval 
from an institutional review board or local ethics committee, and all study participants signed 
informed consent documents at their local institution. 
 
2.2 Image acquisition and segmentation 
High-resolution T1-weighted MRI brain scans were acquired at each of the 20 participating sites. 
Detailed information on scanner sequence and acquisition parameters are found in 
Supplementary Table 2. A description of image and volume segmentation quality control is 
given in Supplementary Note 1. 
 
2.3 Specification of statistical models and coordinated analysis across sites 
The present study involved coordinated analysis of brain structural MRI scans. Our primary 
focus was on the mean volumetric differences between patients with BD and healthy controls in 
seven subcortical brain structures: nucleus accumbens, caudate, globus pallidus, putamen, 
amygdala, hippocampus, and thalamus. We also assessed lateral ventricular volume and total 
intracranial volume (ICV). Within each sample, we used multiple linear regression to quantify 
the differences between BD patients and healthy controls, while accounting for age, sex, and 
differences in head size (ICV) as covariates. For each structure, we calculated effect size 
estimates using Cohen’s d, adjusted for age, sex, and ICV, using the t-statistic from the diagnosis 
predictor variable (coded as patients=1; controls=0)21. As an extension of this model, we 
examined age-by-diagnosis and sex-by-diagnosis interactions using the t-statistic from the 
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interaction predictor variable (while leaving age, sex, and diagnosis predictors in the model) to 
calculate an adjusted Cohen’s d effect size estimate. A description of the meta-analytical 
framework and reported statistics is given in Supplementary Note 2.  
 
2.4 Analysis of differences in diagnosis subtype, mood state, age of illness onset, and 
medications 
In order to investigate brain differences associated with the clinical phenotype we examined 
whether there were detectable differences between BD subtypes, focusing on patients diagnosed 
with BDI and BDII. Methods for determining subtype at each site are given in Supplementary 
Table 3. We performed three separate meta-analyses comparing: BDI patients with controls, 
BDII patients with controls, and BDI with BDII patients following the same model as in Method 
2.3. Similarly, we examined how mood state at the time of scanning influenced brain structure. 
Mood state data was available from 13 sites; patients were categorized into six different 
categories: euthymic, depressed, manic, hypomanic, mixed, and unknown. Tabulated results 
showing the number of subjects with a given mood state at the time of scanning is available in 
Supplementary Table 1. A further description is available mood state, age of illness onset, 
medications and the tests performed can be found in Supplementary Note 3.  
 
2.5 Determination of statistical significance threshold 
In total we performed 225 tests (25 separate analyses looking at 9 mean brain volumes). We 
controlled for multiple comparisons using the False Discovery Rate22 at q = 0.05, which 
corresponds to a P-value significance threshold of Pthresh < 4.91x10-3. Throughout the manuscript 
we report uncorrected P-values, but indicate when a test is significant. 
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3. Results 
 
3.1 Subcortical volume differences between patients with BD and healthy individuals 
 
Patients with BD had significantly lower bilateral mean volumes of the hippocampus (d=-0.232; 
P=3.50x10-7), thalamus (d=-0.148; P=4.27x10-3), and trending significant reduction in 
amygdala (d=-0.108; P=7.65x10-3). Patients also had significantly larger lateral ventricles 
(d=0.260; P=3.93x10-5) than healthy controls. None of the other five structures investigated 
(accumbens, caudate, globus pallidus, putamen, and intracranial volume) showed significant 
differences between BD cases and controls (Figure 1). Mean volumes (and standard errors) 
corrected for age, sex, and intracranial volume (ICV) by site and by diagnosis are available in 
Supplementary Table 7. Unadjusted means split by site and by diagnosis are available in 
Supplementary Table 8. Forest plots of effect sizes for each structure across all sites are shown 
in Supplementary Figure 1a-c. 
 
[Figure 1 here] 
 
 
3.2 Interactive effects of age and sex with bipolar disorder diagnosis 
We examined each of the nine brain structures in our study for age-by-diagnosis and sex-by-
diagnosis interactions. We found significant evidence of decreased hippocampal volume in older 
patients (d=-0.104; P=3.81x10-3). No other structures had significant interactive effects between 
age and diagnosis (Supplementary Table 9). Further, we tested for sex-by-diagnosis 
interactions for each structure and found significant evidence of increased thalamus volume in 
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female patients with bipolar disorder (d=0.202; P=9.65x10-5). No other structures had significant 
interactive effects between sex and diagnosis (Supplementary Table 10). 
 
3.3 Effects of bipolar diagnosis subtype, mood state, and age of onset on subcortical brain 
volumes  
 
We did not find any significant volumetric differences when directly comparing BDI with BDII 
patients (Supplementary Table 11). When comparing BDI and BDII separately to controls, the 
direction of effects (an increase or decrease in volume) for each structure was similar regardless 
of subtype (Supplementary Tables 12-13). However, the magnitude of case-control differences 
on brain volumes was consistently larger in patients with BDI (Figure 2). Patients diagnosed 
with BDI had significantly smaller volumes of the hippocampus (d=-0.203; P=1.31x10-3) and 
amygdala (d=-0.117; P=3.63x10-3), and larger lateral ventricle volumes (d=0.251; P=4.70x10-3) 
compared to controls. In contrast, none of the subcortical brain volumes of BDII patients were 
significantly different from healthy controls. Further, we did not find evidence of an association 
between brain volume differences in any structure with age at onset (Supplementary Table 14).  
 
When examining case/control differences across sites with mood state data available, we found a 
significant increase in lateral ventricular volume in patients compared to controls (d=0.318; 
P=6.06x10-4). Mean hippocampal volume was decreased at a nominally significant level (d=-
0.214; P=0.016), but was not strictly significant after correction for multiple comparisons 
(Supplementary Table 15). We found that a subset of euthymic patients (n=401) had 
significantly decreased hippocampal volume compared to healthy controls (d=-0.233; 
P=1.53x10-3). None of the other structures showed significant differences (Supplementary 
Table 16). In addition, we found that a subset of depressed patients (n=134) showed a trending 
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significant increase in lateral ventricular volume compared to healthy controls (d=0.377; 
P=8.00x10-3). None of the other structures showed significant differences between depressed 
patients and controls (Supplementary Table 17). A direct comparison between euthymic and 
depressed patients was not possible given small sample sizes (the number of studies with both 
euthymic and depressed patients was too low; n=6). 
 
[Figure 2 here] 
 
 
3.4 Medication effects on brain volume in patients with bipolar disorder 
 
We examined the effect of treatment at the time of scanning with lithium, antiepileptics, 
antidepressants, atypical and typical antipsychotics on brain volume in BD patients 
(Supplementary Tables 18-32). We found that patients treated with lithium at the time of 
scanning had larger thalamic volumes compared to patients not taking lithium (d=-0.207; 
P=7.31x10-4). In addition, we found that patients taking antiepileptics had significantly reduced 
hippocampal volume (d=-0.189; P=4.91x10-3) compared to patients not taking antiepileptics 
(Supplementary Figure 2a). We further performed a comparison between the brain volumes of 
patients taking (or not taking) a given medication with the brain volumes of healthy controls. 
Patients that were not taking lithium at the time of scanning had significantly smaller 
hippocampal and thalamic volumes and larger lateral ventricles compared to controls 
(Supplementary Figure 2; Supplementary Table 19) whereas in patients receiving lithium 
therapy hippocampal volumes were comparable to controls.  
 
4. Discussion 
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One of the major points of uncertainty in BD has centered on potential volumetric changes in the 
hippocampus. Two large single-site studies reported a significant hippocampal reduction23, 24 but 
other multisite studies reported no significant differences3-5, 9. Also, smaller hippocampal 
volumes relative to controls were reported in a meta-analysis of BD patients not taking Li11 with 
Cohen's d=-0.36 [-0.55, -0.17] for the left hippocampus and d=-0.38 [-0.63, -0.13] for the right. 
Our estimated Cohen's d=-0.24 [-0.37, -0.12] for non-lithium treated patients is largely in 
agreement. We re-ran the meta-analysis excluding data from the two single-site studies 
mentioned previously (Fears et al., 2014 and Rimol et al., 2010) and observed a nearly identical 
reduction of hippocampal volume (d=-0.220; P=6.95x10-5) (Supplementary Table 33). Upon 
further examination, we found a significant age-by-diagnosis interaction whereby increasing age 
in patients was associated with a decrease in hippocampal volume  (d=-0.104; P=3.81x10-3; 
Supplementary Table 9). This finding may reflect accelerated hippocampal atrophy in patients 
or progressive effects of chronic illness or medication on the hippocampus of patients. 
Our finding of enlarged lateral ventricle volume (Cohen’s d=0.26) is in line with a 
previous mega-analysis by Hallahan and colleagues who reported a d=0.15 for right lateral 
ventricle9. Because the UCLA-BP study includes unaffected relatives as controls we re-ran the 
analysis with that study excluded but this did not change the results (Supplementary Table 35). 
Similarly, exclusion of data with poor age matching (the Halifax and CLING studies) did not 
alter the results (Supplementary Table 36).  
We found a significant reduction in thalamus volume in BD patients as in our previous 
study by Rimol and colleagues23. However, none of the comparable multisite meta-analyses 
showed effects significantly different from zero for the thalamus3-5, 9. To further examine case 
control differences in thalamic volume we undertook additional analysis. First we removed the 
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data from the study by Rimol et al and re-ran the analysis. Case-control differences in thalamic 
volume remained nominally significant (d=-0.11; P=0.013; Supplementary Table 34). Second, 
we re-ran the analysis excluding data from the UCLA-BP study and found that the volume 
reduction in the thalamus remained nominally significant (Supplementary Table 35). Third, 
when the Halifax and CLING samples were removed the effect on thalamus volume was reduced 
but still nominally significant (Supplementary Table 36). Finally, we found evidence of a 
significant sex-by-diagnosis interaction whereby female patients with bipolar disorder had 
significantly increased mean thalamic volume (d=0.202; P=9.65x10-5; Supplementary Table 
10). However, this finding conflicts with previous reports showing no evidence of sex-by-
diagnosis interactions.23 The likely cause of the sex-by-diagnosis interactive effect is unknown at 
this time, but deserves further investigation. 
Previous literature-based meta-analyses had been unable to detect a case-control 
difference in the amygdala. Individual studies in adults with BD had reported either increase or 
no change in amygdala volume25, 26. In contrast, reduced amygdala volume has been repeatedly 
reported in adolescents with BD27 and has been attributed to abnormalities in the developmental 
trajectory of this region in adolescence28. In the present study, case-control differences in 
amygdala volume were only nominally significant when the UCLA-BP, Halifax and CLING 
studies were excluded. No significant effects of age at illness onset (Supplementary Table 14) 
or age-by-diagnosis interactions (Supplementary Table 9) were detected in amygdala volume, 
but this hypothesis might be better tested in a dataset that specifically includes adolescents. 
Further, brain changes over time related to age of illness onset and duration are best studied in 
longitudinal models rather than cross sectional evaluations of large cohorts29, 30. 
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We also examined the effect of FreeSurfer version used for segmentation. We found that 
the between-version agreement (Supplementary Table 6a-h) was largely in line with the 
within-version test-retest reliability (Supplementary Table 5). The only case that seems 
problematic is v4.2 segmentations of the globus pallidus; they seem to be consistently different 
than estimates from the other versions. Only one of datasets in our consortium used v4.2 
(UCLA-BP) and the globus pallidus results are unchanged when running the meta-analysis with 
that study dropped (see Supplementary Table 35). This suggests that subcortical volumes 
segmented with different versions of FreeSurfer are comparable. 
The current findings of subcortical reduction in BD demonstrate the sensitivity of 
volumetric assessment, but do not necessarily implicate pathogenic specificity of subcortical 
structures in BD. van Erp et al. (2015) reported significantly lower hippocampus, thalamus, and 
amygdala volumes and significantly larger lateral ventricles and globus pallidus volumes in 
patients with schizophrenia relative to healthy controls, suggesting that BD and schizophrenia 
may share some common pathogenic mechanisms associated with medial temporal lobe volume 
reduction, which has been hypothesized to be related to excessive glucocorticoid activity31-33. In 
general, the effects of schizophrenia on subcortical brain volumes seem to be stronger than those 
in BD. This trend has been observed in prior single-site studies23, which may be related to the 
relatively greater neurodevelopmental disruption characteristic of schizophrenia34, 35. Similarly, 
Schmaal et al. (2015)36 examined subcortical differences in major depressive disorder (MDD) 
and found significant reductions in the hippocampal volume of MDD patients compared to 
healthy controls. However, the observed effect sizes and pattern of effects seem to be much 
milder than those observed in schizophrenia and BD. 
 We tested whether BDI (n = 862) or BDII (n = 317) are associated with similar brain 
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structural changes. We did not detect any significant differences between patients with BDI and 
BDII diagnoses (Supplementary Table 11) although we would have 80% power to detect 
differences of d=0.087 (Supplementary Note 4). When comparing each subtype separately with 
healthy controls, we found that the pattern of case-control differences in the volume of 
hippocampus, amydala, thalamus, and lateral ventricles was similar for both subtypes 
(Supplementary Tables 12-13). These differences were more pronounced in BDI patients, who 
showed significantly smaller hippocampal and amygdala volumes and significantly larger lateral 
ventricles volumes relative to controls. In contrast, there were no significant differences between 
BDII patients and controls (Figure 2). The literature examining volumetric brain differences in 
BDII is decidedly sparse4, 5 and therefore most but not all4 large literature-based, meta-analyses 
prior to this study grouped all BD subtypes together; likely due to under-reporting of diagnosis 
subtype in individual studies. Furthermore, we found that the effect sizes when examining BDI 
patients alone were slightly smaller than the effect sizes in a model that includes all BD patients 
regardless of subtype (Table 1; Supplementary Table 12). These results in the current samples 
suggest that there were no detectable volumetric differences in subcortical brain structures 
between BDI and BDII. The lack of detected differences between the two subtypes mirrors 
findings in genetics, which also were unable to find significant genetic patterns that distinguish 
BDI and BDII patients despite large sample sizes.37 Future work is needed to further disentangle 
the complex factors that may manifest as distinct bipolar disorder subtypes but have similar 
genetic and volumetric brain patterns.  
 We examined the effect of mood state at the time of scanning to assess whether mood 
moderates bipolar disorder effect size differences. We examined only euthymic and depressed 
mood states compared to controls due to the small sample sizes available of patients scanned 
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during a hypomanic, manic, or mixed state. We found that euthymic patients had significantly 
decreased hippocampal volume compared to controls, which was not detected in depressed 
patients (d=-0.233; P=1.53x10-3). However, none of the other comparisons made were 
significant after multiple comparisons correction. Further, a direct comparison between euthymic 
and depressed patients was not possible given the small sample sizes. As the decrease in 
hippocampal volume was only detected in euthymic patients and not in depressed patients, 
further investigation is warranted. However, caution is needed in interpreting these results given 
differences in sample size between the two groups. A direct comparison between the two groups 
would provide a more definitive assessment in the future. The findings related to mood state 
highlights some of the limitations and weaknesses of our approach whereby neurobiological 
findings cannot readily be mapped onto clinical variables and therefore have limited clinical 
value.  
Medication is arguably one of the most widely debated sources of heterogeneity in the 
brain morphological signature of BD. Much of the BD literature has focused on the effects of 
lithium10, 38, 39. In animal models, lithium has been shown to have neurotrophic effects in the 
hippocampus40 but the mechanism of action is unclear41, 42. We performed the largest comparison 
of BD patients taking (n = 535) and not taking (n = 845) lithium to date (Supplementary Table 
20). We found that patients taking lithium had significantly larger thalamic volumes than patients 
not taking lithium (d=0.207; P=7.31x10-4). However, significant effects of lithium on thalamic 
volume were not detected in other large studies of BD5, 9. We did not observe significant effects 
of lithium in other structures (i.e. hippocampus and amygdala) both of which have been studied 
extensively in the literature5, 9, 11. In addition to the moderating effects of lithium, we examined 
the effects of treatments of four commonly prescribed medication groups: antiepileptics, 
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antidepressants, atypical and typical antipsychotics (Supplementary Figure 2). It is difficult to 
distinguish medication effects on brain volumes from concurrent effects of clinical and 
demographic variables, which interact closely with medication status43, 44. It is possible as well 
that patients that recently stopped taking a particular medication could be considered to be “not 
currently taking a medication” potentially biasing medication effect estimates. The quality of 
information concerning medication effects on brain correlates can be improved using 
longitudinal methods along with tightly controlled medication access and reporting. Further 
longitudinal studies of specific medications are needed to disentangle medication effects on the 
brain from other moderating effects or disease effects. 
A major strength of this study is the large numbers and the ability to harmonize, as far as 
possible the data, which, in the case of imaging data, can be quite a daunting task. However, the 
current study has limitations regarding the heterogeneity of the sample and potential clinical 
confounds. Thus the current findings should be interpreted with caution and need to be replicated 
in independent cohorts. In addition, there are several key limitations to our study: 1) Samples 
were collected and analyzed at different sites; we coordinated our work to maximize 
homogeneity across sites, but differences persist. We showed that scanner field strength, voxel 
volume, and the version of FreeSurfer used for segmentation do not significantly influence (P < 
0.05) the effect size estimates in our analysis (Supplementary Table 37). 2) We examined the 
moderating effects of medication, but caution is needed in interpreting these effects, as 
differences in medication status are likely to interact with illness characteristics. Differences in 
the clinical definitions of medication use and history could potentially confound the estimates in 
this study in unexpected ways. Also, we did not test or account for possible interactions between 
different pharmacological agents although the majority of patients were treated with a 
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combination of agents. However, longitudinal studies of medication effects show that most 
medications are likely to have a null or deleterious effect on the brain45 with the exception of 
lithium, which may have neuroprotective effects39. 3) Most sites used the structured interview 
(DSM-IV) for diagnosis, but some heterogeneity in diagnosis inevitably exists across sites and 
findings should be interpreted with care as they reflect the heterogeneity inherent to a large 
multicenter/multinational comparison. 4) Drug and alcohol dependence or abuse may be another 
source of heterogeneity. These data were not uniformly available within the cohorts in this study, 
but the potential impact of alcohol abuse on ventricular volume has been demonstrated before46, 
and is being analyzed by ENIGMA’s addictions working group. 5) Finally, our hypotheses 
explore the effects of BD on subcortical brain structures and we did not assess effects elsewhere 
in the brain (e.g. cortex, white matter tracts). It is known that neural networks subserve 
emotional processing and regulation and that these almost certainly engage a number of cortical 
structures. However, the current study was limited to sub-cortical data. The analysis of cortical 
data will need another analytical approach, with additional methodological challenges, which is 
currently ongoing. 
 We have demonstrated a pattern of reduced volumes of the hippocampus, thalamus, and 
amygdala in patients with BD. Whereas one should avoid making strong functional 
interpretations based on brain volume differences alone, these findings pertain to neurocircuitry 
implicated in emotional processing and executive behavior47, and nevertheless provide important 
information regarding the neurobiology of BD48. Several functional MRI studies report 
dysfunction in these regions during manic or depressive episodes49, and post mortem gene 
expression studies have also implicated these structures50. Mood-stabilizing drugs may also act 
in this region51. Further, we provide strong statistical evidence of a lack of difference in the 
19 
 
biological signature of BD subtypes. These findings should be interpreted with caution given the 
limitations outlined throughout the manuscript, especially with consideration for the 
heterogeneity involved in using meta-analysis to combine neuroimaging data across sites. 
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Figure Legends 
 
Figure 1. Adjusted Cohen’s d estimates for all BD patients versus controls. Effect sizes for the 
volumetric differences between bipolar disorder (BD) cases and controls (CTL), after accounting 
for age, sex, and intracranial volume over all brain regions of interest. Error bars show mean 
effect size +/- standard error of the mean. Effect sizes were considered significant (marked with 
*) if they exceeded the study-wide significance threshold (P < 4.91x10-3).  
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Figure 2. Adjusted Cohen’s d estimates for BD patients split by diagnosis subtype (type I or type 
II) versus controls. Effect sizes for the volumetric differences between bipolar disorder (BD) 
type I and controls (CTL) are shown in red and BD II and controls are shown in green. All effect 
sizes are reported after accounting for age, sex, and intracranial volume. Error bars show mean 
effect size +/- standard error of the mean. Effect sizes were considered significant (marked with 
*) if they exceeded the study-wide significance threshold (P < 4.91x10-3).  
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Tables 
 
Table 1. Effect sizes differences between all BD cases and controls (Cohen’s d) for the mean volume of each structure controlling for 
age, sex, and intracranial volume. The percent difference is the mean change in volume of a structure in bipolar patients versus 
controls as a percent of the total volume of the structure in controls. I2 gives the estimate of the total heterogeneity as a proportion of 
the total variability for each measure. Uncorrected P-values are reported. Effect size differences are considered significant (marked 
with *) if they exceed P < 4.91x10-3 (see Methods 2.5 for threshold determination). 
 
 
BD - CTL 
(SE) 95% CI 
Percent 
Diff. Z-Score P I
2 Het. P # CTL # BD Hedges’ g 
Lateral Ventricle 0.260 ± 0.063 [0.136 - 0.384] 16.098 4.111 3.93x10-5 65.4 1.64x10-6 2592 1708 0.261 
Thalamus -0.148 ± 0.052 [-0.250 - -0.047] -1.156 -2.858 4.27x10-3 48.6 6.58x10-3 2589 1702 -0.147 
Caudate -0.09 ± 0.051 [-0.190 - 0.010] -0.967 -1.773 0.076 46.0 0.017 2586 1704 -0.090 
Putamen -0.001 ± 0.044 [-0.088 - 0.085] 0.054 -0.034 0.973 30.2 0.073 2588 1704 -0.001 
Globus Pallidus -0.028 ± 0.057 [-0.140 - 0.083] -0.285 -0.498 0.618 57.4 1.53x10-3 2588 1707 -0.028 
Hippocampus -0.232 ± 0.045 [-0.321 - -0.143] -2.010 -5.094 3.50x10-7 33.9 0.049 2582 1705 -0.232 
Amygdala -0.108 ± 0.040 [-0.187 - -0.029] -1.068 -2.667 7.65x10-3 19.4 0.304 2590 1703 -0.107 
Accumbens -0.064 ± 0.063 [-0.187 - 0.060] -0.929 -1.013 0.311 65.1 6.86x10-5 2567 1689 -0.064 
ICV 0.012 ± 0.055 [-0.095 - 0.120] 0.155 0.225 0.822 52.9 1.75x10-4 2594 1710 0.012 
 


